Roivant’s mission is to systematically reduce the time, cost, and risk of delivering new medicines to market by accelerating the development of promising drug candidates to improve the lives of patients and their families. Since its inception in 2014, Roivant has achieved the following critical milestones in support of its vision : built over 20 portfolio companies (Vants). 5 successful IPOs. 10 consecutive positive phase 3 trials. 6 FDA approval...
Roivant’s mission is to systematically reduce the time, cost, and risk of delivering new medicines to market by accelerating the development of promising drug candidates to improve the lives of patients and their families. Since its inception in 2014, Roivant has achieved the following critical milestones in support of its vision: built over 20 portfolio companies (Vants). 5 successful IPOs. 10 consecutive positive phase 3 trials. 6 FDA approvals...
Roivant’s mission is to systematically reduce the time, cost, and risk of delivering new medicines to market by accelerating the development of promising drug candidates to improve the lives of patients and their families. Since its inception in 2014, Roivant has achieved the following critical milestones in support of its vision: built over 20 portfolio companies (Vants). 5 successful IPOs. 10 consecutive positive phase 3 trials. 6 FDA approvals...
Roivant’s mission is to systematically reduce the time, cost, and risk of delivering new medicines to market by accelerating the development of promising drug candidates to improve the lives of patients and their families. Since its inception in 2014, Roivant has achieved the following critical milestones in support of its vision. Built over 20 portfolio companies (Vants). 5 successful IPOs. 10 consecutive positive phase 3 trials. 6 FDA approvals...
Roivant’s mission is to systematically reduce the time, cost, and risk of delivering new medicines to market by accelerating the development of promising drug candidates to improve the lives of patients and their families. Since its inception in 2014, Roivant has achieved the following critical milestones in support of its vision : built over 20 portfolio companies (Vants). 5 successful IPOs. 10 consecutive positive phase 3 trials. 6 FDA approval...
Roivant is a biopharmaceutical company that aims to improve the lives of patients by accelerating the development and commercialization of medicines that matter. Roivant advances its pipeline by creating nimble subsidiaries or “Vants” to develop and commercialize medicines and technologies. Since its inception in 2014, Roivant has achieved the following critical milestones in support of its vision: built over 20 Vants. 11 consecutive positive Pha...
Since its inception in 2014, Roivant Sciences has sought to improve health by rapidly delivering innovative medicines and technologies to patients. We’ve employed a unique, decentralized model of nimble, focused companies (‘Vants’) focused on various therapeutic areas and built around the pursuit of innovation in drug development and technology. Our model is different. Five new medicines have been approved off the Roivant platform. we’ve built fi...
